Smartcells, Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
13
Ending by 2030
Jan 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 7, 2027The maintenance fee for Recombinantly expressed insulin polypeptides and uses thereof (US 9,074,015) comes due Jan 7, 2027. Unpaid by Jul 7, 2027, it lapses early.
- 2 fees due Feb 4 to 25, 2027 · next Feb 4
- 1 fee due Mar 3, 2027The maintenance fee for Conjugate based systems for controlled drug delivery (US 10,398,781) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
- 1 fee due Aug 23, 2027The maintenance fee for Conjugate based systems for controlled drug delivery (US 9,265,838) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,569,231 | Soluble non-depot insulin conjugates and uses thereof In force (reinstated) · From the USPTO record | In force (reinstated) | From the USPTO record | |
| US 8,603,529 | Polynucleotide aptamer-based cross-linked materials and uses thereof In force (reinstated) · From the USPTO record | In force (reinstated) | From the USPTO record | |
| US 8,623,345 | Terminally-functionalized conjugates and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,095,623 | Terminally-functionalized conjugates and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,114,176 | Exogenously triggered controlled release materials and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,265,838 | Conjugate based systems for controlled drug delivery In force · From the USPTO record | In force | From the USPTO record | |
| US 9,579,391 | Conjugate based systems for controlled drug delivery In force · From the USPTO record | In force | From the USPTO record | |
| US 10,398,781 | Conjugate based systems for controlled drug delivery In force · From the USPTO record | In force | From the USPTO record | |
| US 9,463,249 | Crystalline insulin-conjugates In force · From the USPTO record | In force | From the USPTO record | |
| US 8,846,103 | Exogenously triggered controlled release materials and uses thereof In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 18: 1 patent in force now held by others · 2 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 no status recorded